A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19
Brief description of study
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
Clinical Study Identifier: s20-01219
ClinicalTrials.gov Identifier: NCT04516746
Principal Investigator:
Mark J. Mulligan.
Other Investigators:
Sajumon K Joseph,
Ramin Herati,
Andrew Banks Fleming,
Lalitha Parameswaran,
Alexander Mcmeeking,
Stephanie Sterling,
Daniel Sartori,
Sigridh A Munoz-Gomez,
Celia Engelson,
Claudia Patricia De La Matta Rodriguez,
Ellie R. Carmody,
Reny Jose,
Dinuli Hashangani Delpachitra,
Lois Anne Katz,
Sabrina E Felson,
Lars Anders David Green,
Adam Schwartz,
Kevin Douglas Zhang,
Jennifer Nierman Knishinsky,
Asif Noor,
Miloni Haresh Thakker,
Melinda Katz,
Theresa Monahan Fiorito,
Vijaya Soma,
Steven E Carsons,
Angelica Cifuentes Kottkamp,
Rebecca Boas,
Janette Hernandez Torres,
Diane H Johnson,
Reza P Parungao,
Kavita R Kumar,
Jennifer Lee Dong,
Tamia Davis,
Benjamin J Eckhardt,
Jay Pendse,
Urmee Saha,
Martin Backer,
Robert James Ulrich,
Diana Badillo,
Natella Aronova,
Jose O. Aleman,
Melanie R Jay,
Adina Claudia Musta.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
